Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence

• Published in: International journal of hyperthermia Vol. 39; no. 1; pp. 1010 - 1016
• Main Authors: De-Colle, Chiara, Beller, Anna, Gani, Cihan, Weidner, Nicola, Heinrich, Vanessa, Lamprecht, Ulf, Gaupp, Stephan, Voigt, Otilia, Dohm, Oliver, Zips, Daniel, Müller, Arndt-Christian
• Format: Journal Article
• Language: English
• Published: Taylor & Francis 31.12.2022; Taylor & Francis Group
• Subjects: Breast cancer; hyperthermia; radiotherapy; recurrent breast cancer; superficial hyperthermia
• ISSN: 0265-6736; 1464-5157; 1464-5157
• DOI: 10.1080/02656736.2022.2103593

To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor. Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50-70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS). A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed. Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse.